Investors may find better financial performance in Outlook Therapeutics Inc (OTLK)

A share price of Outlook Therapeutics Inc [OTLK] is currently trading at $1.45, up 5.84%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The OTLK shares have gain 16.94% over the last week, with a monthly amount drifted -1.36%, and not seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Outlook Therapeutics Inc [NASDAQ: OTLK] stock has seen the most recent analyst activity on December 02, 2024, when Chardan Capital Markets downgraded its rating to a Neutral. Previously, BTIG Research upgraded its rating to Buy on March 27, 2024, and kept the price target unchanged to $50. On February 15, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $3 on the stock. Guggenheim upgraded its rating to a Buy. CapitalOne upgraded its rating to a Overweight but $5 remained the price target by the analyst firm on December 27, 2023. H.C. Wainwright downgraded its rating to Neutral for this stock on August 31, 2023, and downed its price target to $1. In a note dated August 31, 2023, Chardan Capital Markets downgraded an Neutral rating on this stock.

Outlook Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.87 and $9.29. Outlook Therapeutics Inc [NASDAQ: OTLK] shares were valued at $1.45 at the most recent close of the market.

Analyzing the OTLK fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is 0.0 and Total Capital is 0.0. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.0.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3767 points at the first support level, and at 1.3033 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5067, and for the 2nd resistance point, it is at 1.5633.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Outlook Therapeutics Inc [NASDAQ:OTLK] is 0.32. Also, the Quick Ratio is 0.26, while the Cash Ratio stands at 0.0.

Transactions by insiders

Recent insider trading involved KENYON LAWRENCE A, Chief Financial Officer, that happened on Sep 26 ’24 when 5000.0 shares were purchased.

Related Posts